Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Adagene Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 6-K Quarterly results
07/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Company Presentation",
"Company Presentation"
05/04/2023 6-K Quarterly results
04/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Announces Updates to its Board of Directors"
04/28/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/18/2023 6-K Quarterly results
03/28/2023 6-K Quarterly results
02/09/2023 SC 13G/A FMR LLC reports a 8.8% stake in ADAGENE INC
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Ami Knoefler Adagene 650-739-9952"
12/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’ s Standard-of-Care for First-Line Advanced Liver Cancer SAN DIEGO and SUZHOU, China, December 16, 2022 – Adagene Inc. , a company transforming the discovery and development of antibody-based therapies, today announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’ s ADG126 with Roche’ s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma . The collaboration will utilize Roche’ s MORPHEUS-LIVER platform for rapid and efficient combination development. Under the collaboration, Roche will sponsor and conduct a randomized phase 1b/2 multi-national trial to evaluate the efficacy, safety and pharmacokine..."
11/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Appoints Cuong Do to Board of Directors and Audit Committee"
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors"
08/31/2022 6-K Quarterly results
06/29/2022 6-K Quarterly results
05/27/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels"
05/20/2022 F-3/A Form F-3/A - Registration statement by foreign private issuers: [Amend]
05/13/2022 F-3/A Form F-3/A - Registration statement by foreign private issuers: [Amend]
05/02/2022 DEL AM Form DEL AM - Delaying amendment:
04/29/2022 SC 13D Luo Peter reports a 20.8% stake in Adagene, Inc.
04/26/2022 F-3 Form F-3 - Registration statement by foreign private issuers:
04/26/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research Annual Meeting 2022"
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update"
03/16/2022 6-K Quarterly results
03/09/2022 6-K Quarterly results
03/02/2022 6-K Quarterly results
02/11/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2022 SC 13G Luo Peter reports a 20.2% stake in Adagene Inc.
01/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 SAN DIEGO and SUZHOU, China, January 27, 2022 - Adagene Inc. , a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been dosed in a combination cohort of its anti-CD137 agonist, ADG106, with its anti-CTLA-4 monoclonal antibody , ADG116, in patients with advanced/metastatic solid tumors. The dose escalation cohort will evaluate the safety and tolerability of this novel, proprietary combination in patients with advanced/metastatic solid tumors. “Existing cancer therapies that target CD137 and CTLA-4 are associated with safety concerns, creating a significant unmet need and ..."
01/26/2022 SC 13G WuXi PharmaTech Healthcare Fund I L.P. reports a 9.7% stake in Adagene Inc.
01/26/2022 SC 13G JSR Ltd reports a 9.8% stake in Adagene Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy